- Home
- SBFG vs EVMN Comparison
SBFG vs EVMN Comparison
Compare SBFG & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBFG | EVMN |
|---|---|---|
| Founded | 1983 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2M | 185.1M |
| IPO Year | 2014 | 2025 |
Fundamental Metrics
Financial Performance| Metric | SBFG | EVMN |
|---|---|---|
| Price | $30.42 | $5.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $22.33 |
| AVG Volume (30 Days) | 8.8K | ★ 733.4K |
| Earning Date | 10-22-2026 | 11-07-2026 |
| Dividend Yield | ★ 2.10% | N/A |
| EPS Growth | 27.33 | ★ 75.23 |
| EPS | ★ 1.41 | N/A |
| Revenue | N/A | ★ $13,000,000.00 |
| Revenue This Year | $5.46 | N/A |
| Revenue Next Year | $2.35 | N/A |
| P/E Ratio | $21.60 | ★ N/A |
| Revenue Growth | N/A | ★ 85.71 |
| 52 Week Low | $18.16 | $4.94 |
| 52 Week High | $32.63 | $33.20 |
Technical Indicators
Market Signals| Indicator | SBFG | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 61.69 | 21.01 |
| Support Level | $28.22 | N/A |
| Resistance Level | N/A | $13.35 |
| Average True Range (ATR) | 0.98 | 0.34 |
| MACD | 0.06 | 0.10 |
| Stochastic Oscillator | 56.00 | 11.36 |
Price Performance
Historical ComparisonAbout SBFG SB Financial Group Inc.
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in a single segment, which is Banking.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.